Augmedix downgraded to Hold from Buy at Lake Street

Lake Street analyst Brooks O’Neil downgraded Augmedix to Hold from Buy with a price target of $2.35, down from $3.50, after the company announced last week that it was being acquired by Commure, a privately held portfolio company of private equity firm General Catalyst, for $2.35 per share in cash. The firm thinks it is unlikely there will be another bid and expects the transaction to close upon shareholder approval.